Poet Technologies (POET 23.36%) is trying to turn its AI photonics story into real commercial momentum. The Lumilens order could validate the company's Optical Interposer platform, but investors still face a tense mix of tiny revenue, dilution risk, and execution pressure as the next 12 to 24 months become critical.